AbbVie Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 4AB.F | BMY | PFE | AZN | JNJ.DE | AMGN | |
|---|---|---|---|---|---|---|
| Market cap | 453.44B | 124.85B | 170.14B | 261.25B | 547.89B | 236.98B |
| P/E (TTM) | 84.7 | 13.6 | 39.3 | 25.2 | 40.1 | 27.3 |
| Forward P/E | 18.4 | 9.3 | 10.3 | 14.9 | — | 17.9 |
| Price/book | -85.7 | 5.6 | 2.0 | 5.2 | 7.2 | 20.3 |
| Dividend yield | 2.41% | 4.09% | 5.71% | 1.90% | 2.07% | 2.30% |
| 1-year change | +28.87% | +38.95% | +21.80% | +1.17% | +39.01% | +48.30% |
| Today | +0.16% | −0.91% | −0.86% | −0.22% | −1.69% | −0.14% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All 4AB.F news ›AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?
It completed the acquisition of Apogee Therapeutics to expand its dermatology and respiratory pipeline, and it secured regulatory approvals for multiple therapies in international markets. It secured accelerated regulatory approval for a…
McLaren Teams Up With AbbVie Before Formula 1 United States GP At COTA
As Formula 1 arrives in Austin, Texas for this weekend’s United States Grand Prix at COTA, McLaren has announced a partnership to help provide aid to those who live with immune-mediated disease. McLaren’s new partnership is with global…
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Choosing between established dividend payers and high-growth innovators is a classic investor dilemma. This comparison pits AbbVie (ABBV +2.26%) against Vertex Pharmaceuticals (VRTX +2.53%) to determine which company offers the best…
Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher
Allison Gatlin covers biotechnology, pharmaceuticals and medical technology. She also oversees coverage of top-performing companies for Investor's Business Daily's The New America page. Allison has worked for Investor's Business Daily…
AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community
AbbVie (NYSE: ABBV), a global pharmaceutical leader, and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team. At the center of the partnership is…
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
The Zacks Consensus Estimate for AbbVie’s neuroscience revenues in the third quarter of 2026 is pegged at $3.29 billion. The figure implies year-over-year growth of nearly 16%, with growth expected across most marketed products. Turning to…
AbbVie continues sports push with McLaren; Mercedes and Stripe partner
Through the deal, the company will serve as an official pharmaceutical partner of the McLaren Formula 1 (F1) team, starting at the upcoming United States Grand Prix. AbbVie will use the partnership to promote its ‘Race to Innovate’…
Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie
Welcome to Episode #503 of the Zacks Market Edge Podcast. Every week, host and Zacks stock strategist, Tracey Ryniec, is joined by guests to discuss the hottest investing topics in stocks, bonds, and ETFs and how it impacts your life. This…
AbbVie signs with McLaren Mastercard F1 Team in first global sports sponsorship
Pharma giant AbbVie is the newest Formula One sponsor, signing on with the McLaren Mastercard F1 Team. It is AbbVie’s first foray into motorsports and its first global sports sponsorship. The F1 team deal is the latest in a sponsorship…
AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial. Here’s What It Means for a Stock Up 24% in 2026
The Street now sits about where the stock does. The mean target was 14.6% above the price on March 31. On October 16 it stood at $282.61, 7 cents below the October 19 close, even after Morgan Stanley’s raise to $310 on October 7. Part of…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
theglobeandmail.com37
-
marketscreener.com17
-
fool.com14
-
gurufocus.com14
-
tradingview.com10
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.